Table 1.

Patient demographics and analysis of tumor response

Dosage of GL-ONC1Pt. IDAge (sex)Tumor entityVacc.Dosages (Σ = 24)RECIST 1.1 (prim. target lesions)CHOI (target lesions)
1 × 107 pfu (cohort 1)0162 (f)Gastric1N.d.N.d.
0354 (m)Mesothelioma+4SDaSDa
0447 (f)Gastric+1N.d.N.d.
1 × 108 pfu (cohort 2)0562 (f)Ovarian+4PDaPDa
0640 (f)Ovarian1N.d.N.d.
0755 (f)Ovarian+4SDaPDa
1 × 109 pfu (cohort 3)0865 (f)Primary peritoneal carcinoma+4PDaPDa
0968 (f)CUP (adeno)+2SDbPDb
1039 (m)Mesothelioma3SDbPRb
  • Abbreviations: pfu, plaque-forming unit; f, female; m, male; SD, stable disease; PD, progressive disease; PR, partial response; Pt. ID, patient identity; Vacc., vaccination status; CUP, cancer of unknown primary; and N.d., not determined.

  • aAfter final PET-CT.

  • bAfter midterm CT.